newsfilter
← Latest News
GlobeNewswire·

Immutep Quarterly Activities Report Q3 FY26

Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagimod alfa development